Revance to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023

Rhea-AI Summary

Revance Therapeutics, Inc. (RVNC) will announce its fourth quarter and full year 2022 financial results on February 28, 2023, after market close. A conference call is scheduled for 4:30 p.m. ET to discuss these results and provide a corporate update. Interested participants can join by dialing (800) 715-9871 with conference ID: 1286316 or via the webcast available on their website. A replay will be accessible from February 28 until March 28, 2023. Revance is recognized for its innovative aesthetic and therapeutic solutions, including DAXXIFY® and a biosimilar collaboration with Viatris Inc.

Positive

• Scheduled financial results and conference call indicate transparency and communication with investors.
• Expansion into the biosimilar market through partnership with Viatris.
• Innovative products like DAXXIFY® and a comprehensive aesthetic portfolio.

Negative

• None.

Conference Call Scheduled for Tuesday, February 28, 2023 at 4:30 p.m. ET.

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (RVNC), today announced that the company will release fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update.

Individuals interested in listening to the conference call may do so by dialing (800) 715-9871 and reference conference ID: 1286316, or from the webcast link in the investor relations section of the company's website at: www.revance.com.

A replay of the call will be available beginning February 28, 2023, at 4.30 p.m. PT / 7.30 p.m. ET to March 28, 2023 at 4.30 p.m. PT / 7.30 p.m. ET. To access the replay, dial (800) 770-2030 and reference conference ID: 1286316. The webcast will be available in the investor relations section on the company's website for 90 days following the completion of the call.

About Revance

Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that elevate patient and physician experiences. Revance’s aesthetics portfolio of expertly created products and services, including DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection, the RHA® Collection of dermal fillers, and OPUL®, the first-of-its-kind Relational Commerce platform for aesthetic practices, deliver a differentiated and exclusive offering for the company’s elite practice partners and their consumers. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection, which will compete in the existing short-acting neuromodulator marketplace. Revance’s therapeutics pipeline is currently focused on muscle movement disorders including evaluating DAXXIFY® in two debilitating conditions, cervical dystonia and upper limb spasticity.

Revance is headquartered in Nashville, Tennessee, with additional office locations in Newark, Pleasanton and Irvine, California. Learn more at www.Revance.com, www.RevanceAesthetics.com, DAXXIFY.RevanceAesthetics.com, or connect with us on LinkedIn.

“Revance” and the Revance logo, DAXXIFY®, and OPUL® are registered trademarks of Revance Therapeutics, Inc.

Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230221005804/en/

Investors

Revance Therapeutics, Inc.:

Jessica Serra, 510-279-6886

jessica.serra@revance.com

or

Gilmartin Group, LLC.:

Laurence Watts, 619-916-7620

laurence@gilmartinir.com

Media

Revance Therapeutics, Inc.:

Sara J. Fahy, 949-887-4476

sfahy@revance.com

Source: Revance Therapeutics, Inc.

FAQ

When will Revance Therapeutics announce its financial results for Q4 2022?

Revance Therapeutics will announce its financial results on February 28, 2023.

What time is the Revance Therapeutics conference call scheduled?

The conference call is scheduled for 4:30 p.m. ET on February 28, 2023.

How can I listen to the Revance Therapeutics conference call?

You can listen by dialing (800) 715-9871 or via the webcast on Revance's investor relations website.

What innovative products does Revance Therapeutics offer?

Revance offers products such as DAXXIFY® for injections and the RHA® Collection of dermal fillers.

Is Revance Therapeutics partnering with any other company?

Yes, Revance is partnering with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA.